Important note
Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. You need to consult the Evidence of Coverage to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Senior Care members, this policy will apply unless Medicare policies extend coverage beyond this Medical Policy & Criteria Statement. Senior Care policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS’s Coverage Issues Manual can be found on the CMS website.

SERVICE: Dermatoscopy

PRIOR AUTHORIZATION: Not applicable.

POLICY: SWHP considers Dermatoscopy (also known as dermoscopy, epiluminescence microscopy (ELM, DELM), skin surface microscopy, skin videomicroscopy, or incidence light microscopy) using either direct inspection, digitization of images, or computer-assisted analysis, incidental to a dermatologic exam and not separately reimbursable. There is no established code for this procedure.

OVERVIEW: Dermatoscopy describes a family of noninvasive techniques that allow in vivo microscopic examination of skin lesions, and is intended to help distinguish between benign and malignant pigmented skin lesions. The technique involves application of immersion oil to the skin, which eliminates light reflection from the skin surface and renders the stratum corneum transparent. Using a magnifying lens, the structures of the epidermis and epidermal-dermal junction can then be visualized. A handheld or stereomicroscope may be used for direct visual examination. Digitization of photographic images, typically after initial visual assessment, permits storage and facilitates their retrieval, and is often used for comparison purposes if a lesion is being followed up over time.

A variety of dermatoscopic features have been identified that are suggestive of malignancy, including pseudopods, radial streaming, the pattern of the pigment network, and black dots. These features in combination with other standard assessment criteria of pigmented lesions, such as asymmetry, borders, and color, have been organized into algorithms to enhance the differential diagnosis of pigmented skin lesions. Dermatoscopic images may be assessed by direct visual examination or by review of standard, digitized or ultraviolet photographs. Digitization of images, either surface or dermatoscopic images, may permit qualitative image enhancement for better visual perception and discrimination of certain features, or actual computer-assisted diagnosis.

There is a lack of rigorous data that demonstrates the impact of this technology on clinical outcomes, and no studies were identified relating specifically to the use of ultraviolet photography used for dermatoscopy. While there is extensive literature regarding dermatoscopy, the literature is inconclusive regarding its clinical role in the management of pigmented skin lesions, (i.e., as a technique to either select or deselect lesions for excision),
which is considered the gold standard. There is inadequate documentation regarding the clinical value of dermatoscopy in various clinical situations.

**MANDATES:** None

**CODES:**

<table>
<thead>
<tr>
<th>CPT Codes Not Covered:</th>
<th>96904 - Whole body integumentary photography, for monitoring of high risk patient with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0044T - Whole body integumentary photography for monitoring of high-risk patients with dysplastic nevus syndrome or familial melanoma</td>
</tr>
<tr>
<td></td>
<td>0045T - Whole body integumentary photography for monitoring of high-risk patients; with history of dysplastic nevi or personal history of melanoma</td>
</tr>
</tbody>
</table>

**CMS:** There are no NCDs or LCDs issued.

**POLICY HISTORY:**

<table>
<thead>
<tr>
<th>Status</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>12/6/2010</td>
<td>New policy</td>
</tr>
<tr>
<td>Reviewed</td>
<td>12/6/2011</td>
<td>Reviewed</td>
</tr>
<tr>
<td>Reviewed</td>
<td>10/4/2012</td>
<td>Reviewed</td>
</tr>
<tr>
<td>Reviewed</td>
<td>5/23/2013</td>
<td>Revised references and codes</td>
</tr>
<tr>
<td>Reviewed</td>
<td>4/24/2014</td>
<td>No significant changes made.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>4/30/2015</td>
<td>No changes made.</td>
</tr>
</tbody>
</table>

**REFERENCES:**

The following scientific references were utilized in the formulation of this medical policy. SWHP will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order.

25. Rakowska, A; Sliwinńska, M; Czuwara, J; Olszewska, M; Rudnicka, L. Dermoscopy as a tool for rapid diagnosis of monilethri”\). Journal of Drugs in Dermatology (2007) 6 (2): 222–4. PMID 17373184